Anavex Life Sciences climbs after Alzheimer's drug trial data

Anavex Life Sciences

09/09/2025 13:53

** Shares of drug developer Anavex Life Sciences AVXL.O rise 2.7% to $9.60 premarket

** Co says its experimental Alzheimer's drug, blarcamesine, slowed memory loss among early-stage patients after 48 weeks of treatment in mid-to-late stage trial

** Patients who took daily 30 mg dose of blarcamesine in trial showed "barely detectable" decline on key cognitive tests, co says

** Blarcamesine is once-daily oral pill that works by activating protein SIGMAR1 to help clear damaged proteins in brain, slowing cognitive decline in early Alzheimer's patients

** As of last close, stock down 13% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))